SAR EXAM 3 QUESTIONS WITH CORRECT
ANSWERS 2025
NeedHtheH3-phenolHgroupHtoHbindHtoHtheHAF-2HonHestrogenHreceptorHtoHexpressHtheHEREH-
HCORRECTHANSWERH-EstrogenHReceptorHBinding
HowHdoesHPTHHcauseHboneHformation?H-HCORRECTHANSWERH-
increasedHGsHstimullation,HACHrelease,HcampHincrease
CampHincreaseHcausesHanti-apopticHeffectHonHosteoblastsHandHreleasesHIGF-
1HtoHinduceHOBHdifferentiation
HowHdoHglucocorticoidsHpromoteHboneHresorption?H-HCORRECTHANSWERH-
1.HPromoteHOBHandHosteocyteHapoptosis
2.HInhibitHOBHmaturation
•TheHdisulfideHbondHbetweenHCys-1HandHCys-7HisHcriticalHforHactivity.
Calcitonin-HsalmonHisHapproximatelyH50-
foldHmoreHpotentHthanHhumanHcalcitoninHwithHaHlongerHdurationHofHactionH-HCORRECTHANSWERH-
SARHofHsalmonHcalcitonin
IsHmoreHpotentH-HCORRECTHANSWERH-4-hydroxytamoxifenHSAR
•howeverHbecauseHofHtheHpresenceHofHaHsemi-
rigid,HamineHcontainingHsideHchain,HraloxifeneHisHunableHtoHinteractHwithHAF-2H.
•AsHaHresult,HinteractionHwithHEREHisHpreventedHandHantiestrogenicHactionHisHobservedHinHreprodu
ctiveHtissues.
, HasHlessHsideHeffects
•ThisHselectiveHactionHmeansHthatHthisHagentHdoesHnotHincreaseHtheHriskHofHendometrialHorHbreast
Hcancer,HasHisHtheHcaseHwithHlong-termHtamoxifenHtherapy.H-HCORRECTHANSWERH-SARHofHraloxifen
SARHofHTeriperitideH-HCORRECTHANSWERH-SARHofHTeriperitide
•TeriparatideHisHrecombinantHhumanHPTHH1-
34HwhichHisHtheHbiologicallyHactiveHportionHofHtheHendogenouslyHproducedHpre-prohormone.
•firstHapprovedHbone-formingHagent.
•Although.HFull-lengthHhumanHPTH(1-
84)HisHapprovedHforHsuchHusesHinHsomeHcountriesHbutHnotHinHtheHUnitedHStatesH(becauseHofHhyper
calcemiaHandHotherHadverseHeffectsHfromHtheHmarketedHdose)
•EssentialHforHBinding:H-OHHgroupsHatHpositionH3HandH17
•-OHHatH3HbindsHtoHArg394H(helix6)HandHGlutamateH353H(helixH3)
•-OHHatH17HbindsHtoHHistidineH524HatHHelixH11H-HCORRECTHANSWERH-SARHofHestrogen
SARHbiphosphonateH-HCORRECTHANSWERH-SARHofHbiphosphonate
•TheHhydroxylHsubstituentH(R1)HmaximizesHtheHaffinityHofHtheHagentHforHtheHhydroxyapatite
•TheH2HphosphonateHgroups,HtogetherHwithHaHhydroxylHgroupHatHtheHR1Hposition,HimpartHhighHaffi
nityHforHboneHmineralHandHactHasHaH"boneHhook,".HThisHallowsHrapidHandHefficientHtargetingHofHbis
phosphonatesHtoHboneHmineralHsurfaces.
HydrophillicHringHonHtheHright:HincreasesHwaterHsolubility,HhelpsHinHtranslocationHandHtransportati
on
SteroidHringHonHleft:HsetsHonsetHofHactionHandHdurationHofHeffect
ANSWERS 2025
NeedHtheH3-phenolHgroupHtoHbindHtoHtheHAF-2HonHestrogenHreceptorHtoHexpressHtheHEREH-
HCORRECTHANSWERH-EstrogenHReceptorHBinding
HowHdoesHPTHHcauseHboneHformation?H-HCORRECTHANSWERH-
increasedHGsHstimullation,HACHrelease,HcampHincrease
CampHincreaseHcausesHanti-apopticHeffectHonHosteoblastsHandHreleasesHIGF-
1HtoHinduceHOBHdifferentiation
HowHdoHglucocorticoidsHpromoteHboneHresorption?H-HCORRECTHANSWERH-
1.HPromoteHOBHandHosteocyteHapoptosis
2.HInhibitHOBHmaturation
•TheHdisulfideHbondHbetweenHCys-1HandHCys-7HisHcriticalHforHactivity.
Calcitonin-HsalmonHisHapproximatelyH50-
foldHmoreHpotentHthanHhumanHcalcitoninHwithHaHlongerHdurationHofHactionH-HCORRECTHANSWERH-
SARHofHsalmonHcalcitonin
IsHmoreHpotentH-HCORRECTHANSWERH-4-hydroxytamoxifenHSAR
•howeverHbecauseHofHtheHpresenceHofHaHsemi-
rigid,HamineHcontainingHsideHchain,HraloxifeneHisHunableHtoHinteractHwithHAF-2H.
•AsHaHresult,HinteractionHwithHEREHisHpreventedHandHantiestrogenicHactionHisHobservedHinHreprodu
ctiveHtissues.
, HasHlessHsideHeffects
•ThisHselectiveHactionHmeansHthatHthisHagentHdoesHnotHincreaseHtheHriskHofHendometrialHorHbreast
Hcancer,HasHisHtheHcaseHwithHlong-termHtamoxifenHtherapy.H-HCORRECTHANSWERH-SARHofHraloxifen
SARHofHTeriperitideH-HCORRECTHANSWERH-SARHofHTeriperitide
•TeriparatideHisHrecombinantHhumanHPTHH1-
34HwhichHisHtheHbiologicallyHactiveHportionHofHtheHendogenouslyHproducedHpre-prohormone.
•firstHapprovedHbone-formingHagent.
•Although.HFull-lengthHhumanHPTH(1-
84)HisHapprovedHforHsuchHusesHinHsomeHcountriesHbutHnotHinHtheHUnitedHStatesH(becauseHofHhyper
calcemiaHandHotherHadverseHeffectsHfromHtheHmarketedHdose)
•EssentialHforHBinding:H-OHHgroupsHatHpositionH3HandH17
•-OHHatH3HbindsHtoHArg394H(helix6)HandHGlutamateH353H(helixH3)
•-OHHatH17HbindsHtoHHistidineH524HatHHelixH11H-HCORRECTHANSWERH-SARHofHestrogen
SARHbiphosphonateH-HCORRECTHANSWERH-SARHofHbiphosphonate
•TheHhydroxylHsubstituentH(R1)HmaximizesHtheHaffinityHofHtheHagentHforHtheHhydroxyapatite
•TheH2HphosphonateHgroups,HtogetherHwithHaHhydroxylHgroupHatHtheHR1Hposition,HimpartHhighHaffi
nityHforHboneHmineralHandHactHasHaH"boneHhook,".HThisHallowsHrapidHandHefficientHtargetingHofHbis
phosphonatesHtoHboneHmineralHsurfaces.
HydrophillicHringHonHtheHright:HincreasesHwaterHsolubility,HhelpsHinHtranslocationHandHtransportati
on
SteroidHringHonHleft:HsetsHonsetHofHactionHandHdurationHofHeffect
